<SEC-DOCUMENT>0001654954-21-012947.txt : 20211208
<SEC-HEADER>0001654954-21-012947.hdr.sgml : 20211208
<ACCEPTANCE-DATETIME>20211208144425
ACCESSION NUMBER:		0001654954-21-012947
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20211207
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211208
DATE AS OF CHANGE:		20211208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ainos, Inc.
		CENTRAL INDEX KEY:			0001014763
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				751974352
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20791
		FILM NUMBER:		211478464

	BUSINESS ADDRESS:	
		STREET 1:		AINOS, INC.
		STREET 2:		8880 RIO SAN DIEGO DRIVE SUITE 800
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92108
		BUSINESS PHONE:		858-869-2986

	MAIL ADDRESS:	
		STREET 1:		AINOS, INC.
		STREET 2:		8880 RIO SAN DIEGO DRIVE SUITE 800
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARILLO BIOSCIENCES INC
		DATE OF NAME CHANGE:	19960516
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aimd_8k.htm
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:amar="http://amarbio.com/20211207"><head><title>aimd_8k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:left;font:10pt times new roman"><div style='display:none;text-align:left;font:10pt times new roman;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2021-12-07to2021-12-07">0001014763</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2021-12-07to2021-12-07" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='amar-20211207.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2021-12-07to2021-12-07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-07</xbrli:startDate><xbrli:endDate>2021-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">________________________</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="font-size:18pt"><strong>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2021-12-07to2021-12-07">8-K</ix:nonNumeric></strong></span>&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">________________________</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CURRENT REPORT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Pursuant to Section 13 or 15(d)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>of the Securities Exchange Act of 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2021-12-07to2021-12-07" format="ixt:datemonthdayyearen">December 7, 2021</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:72%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2021-12-07to2021-12-07">AINOS, INC</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="width:72%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Exact name of registrant as specified in its charter)</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;<ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2021-12-07to2021-12-07" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2021-12-07to2021-12-07">0-20791</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2021-12-07to2021-12-07">75-1974352</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(State or other Jurisdiction</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>of Incorporation)</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Commission</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>File Number)</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(IRS Employer</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Identification No.)</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:71%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2021-12-07to2021-12-07">8880 Rio San Diego Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="From2021-12-07to2021-12-07">Ste. 800</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2021-12-07to2021-12-07">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="From2021-12-07to2021-12-07">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2021-12-07to2021-12-07">92108</ix:nonNumeric> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2021-12-07to2021-12-07">858</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2021-12-07to2021-12-07">869-2986</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="width:71%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address and telephone number, including area code, of registrant's principal executive offices)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="text-decoration:underline"><strong>AMARILLO BIOSCIENCES, INC.</strong><br /></span><strong>(Former name or former address if changed since last report.)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="From2021-12-07to2021-12-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="From2021-12-07to2021-12-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="From2021-12-07to2021-12-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="From2021-12-07to2021-12-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Securities registered pursuant to Section 12(b) of the Act: None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2021-12-07to2021-12-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Item 1.01 Entry Into a Material Definitive Agreement.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">On December 7, 2021, Ainos, Inc., a Texas corporation (the &#8220;Company&#8221;) entered into an Oral Antiviral Therapy Development and Sales Agreement (&#8220;Agreement&#8221;) with InnoPharmax, Inc., a Taiwan corporation (&#8220;InnoPharmax&#8221;). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Pursuant to the Agreement, the Company and InnoPharmax agreed to jointly develop and promote an orally administered cytotoxin-induced complementary combined therapy (&#8220;CICCT&#8221;) for the treatment of COVID-19 and potentially other viral infections. The companies plan to develop this combined therapy leveraging Ainos&#8217; VELDONA<sup>&#174;</sup> drug platform based on low-dose oral interferon along with InnoPharmax&#8217;s orally administered antiviral drug, GemOral<sup>&#174;</sup>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Initially, both Parties will undertake and equally share in the costs for preclinical research, animal trials, and clinical trials of subjects that have tested positive for COVID-19 and thereafter, if the foregoing preclinical trials are successful, the Company will conduct additional clinical trials and be responsible for obtaining regulatory approvals at its own cost. InnoPharmax is obligation to provide technical support for the clinical trials and regulatory approvals for the CICCT product.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">If the planned CICCT product is approved by relevant regulators, the Parties agreed to equally share net profits and jointly license regional licensing, if any, of the CICCT products. The Company will be responsible for global sales, marketing and after-sales service and InnoPharmax is responsible for quality control oversight of research and development, disease indication development, and manufacturing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The Agreement is effective December 7, 2021 and has a term of twenty (20) years with six (6) month extensions thereafter, subject to early termination rights. The Agreement includes a mutually agreed ten million dollar ($10,000,000) punitive damages and contract damages stipulation if either Party breaches its confidentiality and non-disclosure duties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Item 7.01 Regulation FD Disclosure</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">On December 7, 2021, the Company issued a press release relating to the execution of the Agreement. A copy of the press release is furnished herewith as Exhibit 99.1.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The information furnished with this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Item 9.01 Financial Statements and Exhibits.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The following exhibits are filed as part of this report:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><em>(d) Exhibits</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit</strong> <strong>No.</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex991.htm">99.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex991.htm">Press Release</a></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160;</td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Ainos, Inc.</strong></p></td><td></td></tr><tr style="height:15px"><td style="width:50%;">&#160;</td><td style="width:5%;">&#160;</td><td style="width:35%;">&#160;</td><td style="width:10%;">&#160;</td></tr><tr style="height:15px"><td>Date: December 8, 2021</td><td>By:</td><td style="BORDER-BOTTOM: black 1px solid;">/s/ Chun-Hsien Tsai </td><td></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chun-Hsien Tsai </p></td><td>&#160;</td></tr><tr style="height:15px"><td>&#160;</td><td>Title: </td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer</p></td><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT INDEX</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;&#160;&#160; </p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit No.</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex991.htm">99.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex991.htm">Press Release</a></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aimd_ex991.htm
<DESCRIPTION>ADDITIONAL EXHIBITS
<TEXT>
<html><head><title>aimd_ex991.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Ainos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infection</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>SAN DIEGO, CA / ACCESSWIRE / December 7, 2021 /</strong> Ainos, Inc. ("we", "our", or the "company"), (OTC PINK: AIMD), a diversified healthcare company engaged in the discovery and development of pharmaceutical, medical devices and biotech products announced it entered into a Development and Sales Agreement with InnoPharmax, Inc. (&#8220;InnoPharmax&#8221;), a specialty pharmaceutical company focused in the development and commercialization of products for the treatment of infectious diseases, immunology, and oncology.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Ainos and InnoPharmax agreed to jointly develop and promote an orally administered cytotoxin-induced complementary combined therapy (&#8220;CICCT&#8221;) for the treatment of COVID-19 and potentially other viral infections. The companies plan to develop this combined therapy leveraging Ainos&#8217; VELDONA<sup>&#174;</sup> drug platform based on low-dose oral interferon along with InnoPharmax&#8217;s orally administered antiviral drug, GemOral<sup>&#174;</sup>. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#8220;We believe that CICCT combined with interferon may increase the production of human cytotoxin, an autoimmune hormone that is reported to inhibit viruses,&#8221; said Ainos&#8217; CEO Chun-Hsien Tsai. &#8220;The high level of COVID-19 cases -- still nearly 100,000 new confirmed cases despite increasing vaccination rates reported each day and more than 1,000 confirmed deaths during the past week in the U.S. alone according to the U.S. Department of Health and Human Services &#8211; suggests that the world needs a broader range of effective antiviral therapies,&#8221; he observed. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#8220;For COVID-19 patients we are particularly focused on cytokine storm, an imbalanced innate immunity response that causes severe inflammation in the lungs and necrosis associated with a high IL-6/IFN ratio,&#8221; remarked Chun-Hsien Tsai. &#8220;We believe a combined therapy of Ainos&#8217; VELDONA<sup>&#174;</sup> drug therapeutic and InnoPharmax&#8217;s D07001 GemOral<sup>&#174;</sup> can effectively increase the secretion of interferon in the human body by stimulating secretion <em>in vivo</em> and <em>in vitro</em>, thereby inhibiting the replication of coronavirus and effectively enhancing immunoreaction,&#8221; Mr. Tsai said.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The companies plan to jointly perform animal and investigator-initiated trials for safety and efficacy testing in Taiwan early next year and conduct a subsequent Phase III clinical trial with the goal of applying for regulatory approvals, including U.S. emergency use authorization if available, sometime in the third quarter of 2022. Upon commercialization, Ainos will be responsible for global sale in countries for which the product is approved for uses, and InnoPharmax will be responsible for drug production and manufacturing. The two parties will share profits on drug sales. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#8220;Given the current market for other similar proposed antiviral regimens, we assume the cost per treatment globally to be approximately USD 500, subject to change in accordance with market dynamics,&#8221; Mr. Tsai said.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">According to a press release by the U.S. National Institutes of Health published on October 18, 2021, &#8220;Laboratory studies have shown that the normal type 1 interferon response is suppressed after infection with SARS-CoV-2, the virus that causes COVID-19. In addition, previous studies of hospitalized patients with COVID-19 demonstrated reduced production of interferon in response to SARS-CoV-2 infection in many patients, and this was associated with more severe disease.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Ainos&#8217; VELDONA<strong>&#174;</strong> is a low-dose oral interferon alpha (IFN-&#945;) therapeutic, with the ability to &#8220;interfere&#8221; with viral replication by protecting cells from virus infections, spread and cancer cell division. Interferon alpha (IFN-&#945;) also has various antitumor activities including the direct induction of cytotoxicity and the activation of NK cells and antibody-dependent cell-mediated cytotoxicity. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Studies have shown that type I interferon, IFN-&#945;, (B lymphocytes and monocyte) and IFN-&#946; (fibroblast) not only directly inhibits the replication of virus cells but also stimulates the operation of the immune system. Type II interferons, including IFN-&#947; (T lymphocyte), have the functions of antivirus, activating phagocytes and inducing expression of MHC molecular. We plan to investigate combining the functions of type I and type II interferons with the hopes of more effectively inhibiting the replication of virus and enhance immunoreaction. We are focused on reducing the continuous secretion of inflammatory cytokine to avoid severe pneumonia reactions and cytokine storms.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">InnoPharmax&#8217;s oral drug D07001 GemOral&#174; inhibits inflammatory cytokine, such as IL-6 and CCL2, and also induces the production of interferon-stimulated gene (ISG) and interferon (IFN-b and IFN-&#955;). Gemcitabine, a key compound in GemOral&#174;, can improve the performance of type II interferon-&#947; and CD8+ of immune cells. Gemcitabine can replace cytidine to be embedded in DNA or RNA during the process of nucleotide replication, resulting in failure of nucleic acid replication and cytotoxicity which is beneficial to inhibit the replication and the growth of virus in the body. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>Overview of VELDONA</em></strong><em><sup>&#174;</sup></em><strong><sup> </sup></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">VELDONA<sup>&#174;</sup><sup> </sup>may be superior to high dose injectable interferon in safety, cost and ease of administration.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Administered sublingually as small tablet (lozenge) in doses ten thousand times less than injectable interferon</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Binds to surface (mucosal) cells in the mouth/throat stimulating white blood cells and activates the immune system</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">VELDONA<sup>&#174;</sup> not aimed at a single disease or viral infection (as current antiviral and vaccine candidates), but used to activate overall immune system to prevent and treat a broad range of diseases and viruses such as Covid 19</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The effectiveness of VELDONA<sup>&#174;</sup> in research studies. VELDONA<sup>&#174;</sup> was orally administered to C57BL/6J mice once a day. After 7 days, the mice were infected with human influenza virus (H1N1 virus) and the control group was given placebo to mice for seven consecutive days. For comparison, the oral low-dose VELDONA<sup>&#174;</sup> group significantly reduced (P&lt;0.05) virus replication in the lungs of mice and reduced death. (Refrence: Beliharz M et al., Biochem Biophys Res Commun 335:740-44, 2007)</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="aimd_ex991img1.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>Overview of GemOral</em></strong><sup>&#174;</sup><strong><em><sup> </sup></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">GemOral<sup>&#174;</sup> is a product that encompasses three critical characteristics: Oral Formulation, Antiviral Potency, and Innate Immune Promotion which can promote the production of interferon and inhibit the production of inflammatory cytokine. GemOral<sup>&#174;</sup> is tailored for COVID-19 treatment.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">With FDA approved API, Phase I &amp; Ib clinical safety data, and GMP grade commercial level mass-manufacture capacity in the U.S., GemOral<sup>&#174;</sup> is ready to launch a pivotal clinical trial for COVID-19 patients.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">By providing an oral, convenient, and early-stage treatment, GemOral<sup>&#174;</sup> aims to offer a solution to slow down public viral spread, lower the cases of severe COVID-19, reduce healthcare burden, and eventually lead to a &#8220;same as flu&#8221; mortality rate.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">GemOral<sup>&#174;</sup> was commissioned by the National Taiwan University School of Medicine to conduct the Vero E6 cell test. The effective concentration (EC50) of the antiviral is about 1.1uM, and the concentration (CC50) that will damage the cells is about 52uM, which is about 48 times the effective concentration of the antiviral. It shows that GemOral<sup>&#174;</sup> can kill a virus without harming the cells. The following chart shows the results of the test conducted by the National Taiwan University School of Medicine:</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="aimd_ex991img2.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;&nbsp;</p> <table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:20%;vertical-align:top; background-color:#ffff80;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Brand Name</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">GemOral<sup>&#174;</sup></p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top; background-color:#ffff80;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Active Pharmaceutical Ingredient</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Gemcitabine</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top; background-color:#ffff80;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SKU</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">40mg/20mg soft-gel capsule</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top; background-color:#ffff80;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Manufacture Status</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">GMP grade mass-manufactured for clinical and commercial use in <strong>US</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:20%;vertical-align:top; background-color:#ffff80;"> <p style="MARGIN: 0px; text-align:center;"><strong>Clinical Development</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">&#8226;&nbsp;&nbsp;&nbsp;&nbsp; (IIT, Compassionate Use) COVID-19</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">&#8226;&nbsp;&nbsp;&nbsp;&nbsp; Phase I study in oncology patients (completed)</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">&#8226;&nbsp;&nbsp;&nbsp;&nbsp; Phase Ib study in GI cancer patients (INNO-GO-03) (completed)</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">&#8226;&nbsp;&nbsp;&nbsp;&nbsp; Phase II/III study for 2<sup>nd </sup>line Cholangiocarcinoma (On-Going)</p> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top; background-color:#ffff80;"> <p style="MARGIN: 0px; text-align:center;"><strong>Route of Administration</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">Oral Administration (P.O.)</p></td></tr> <tr style="height:15px"> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top; background-color:#ffff80;"> <p style="MARGIN: 0px; text-align:center;"><strong>Regimen</strong></p></td> <td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;vertical-align:top;"> <p style="margin:0px">Oncology(current): 1000mg/m<sup>2 </sup>intravenous infusion, 3 QW doses for a four-week cycle.</p> <p style="margin:0px">Anti-Virus (proposed): 20mg oral administration, QD for 5 days.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>About Ainos, Inc.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Ainos, Inc., a Texas corporation (f/k/a Amarillo Biosciences, Inc.), is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. The Company is currently focusing on point-of-care testing rapid test kit products that include diagnostics for COVID-19 (SARS-CoV2-Antigen Rapid Test), pneumonia, vaginitis and helicobacter pylori (H. pylori) bacterial infection. Ainos is transforming itself into a diversified MedTech leader through strategic relationships with innovative companies such as InnoPharmax. We are using our VELDONA<strong>&#174;</strong> drug platform in our joint development arrangement with InnoPharmax. VELDONA<strong>&#174;</strong> stands for very low-dose interferon alpha (IFN-&#945;) that is orally administered and absorbed through the oral mucosa to initiate the innate immunity. VELDONA<strong>&#174;</strong> is the company&#8217;s registered trademark in Taiwan. For more information about the company please refer to: www.ainos.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>About InnoPharmax, Inc.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Innopharmax is a biopharmaceutical company focusing on the research and development platform of new oral drug formulations. Its main platform technology, OralPAS (Pro), can convert injectable drugs (such as insulin) into oral administration. The company develops and commercializes oral formulations with potential new drugs developed by the company or with its partners. InnoPharmax&#8217;s vision is to become a leader in the development of new drugs and dosage-forms in Asia through formulation technology. Test results from cell experiments by Innopharmax show that GemOral<strong>&#174;</strong> inhibits the infection caused by SARS-CoV-2 virus. The effective concentration (EC50) is about 1.1uM and the concentration (CC50) that causes damage to cells is 52.4uM. Gemcitabine, the main component of D07001, promotes autoimmunity at low concentrations which increases the secretion of interferon and reduces the secretion of inflammatory cytokine. Gemcitabine, which is same as Merck's oral drug -MK4482, is an analog of cytidine that inhibits the replication of virus in cells and has high activity on cancer cells. Innopharmax has completed the Phase I clinical study and plans to move forward to Phase II/III. InnoPharmax&#8217;s drug development and product lines include anti-infective drugs, cancer drugs, immune drugs, antidiabetic drug and rare disease drugs. GemOral<strong>&#174;</strong> is the company&#8217;s registered trademark in Taiwan. For more information about the company please refer to: www.innopharmax.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><u>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "project," 'target," "future," "seek," "likely," "strategy," "may," "should," "will," and similar references to future periods. Forward-looking statements are based only on our current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, the following: the cost of production and sales potential of the planned drug treatments announced in this press release; the impact of final approvals from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) or other regulatory bodies for the planned drug treatments including the availability of emergency use authorization; the Company's limited cash and history of losses; the Company's ability to achieve profitability; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; the Company's ability to manufacture any products it develops; general economic conditions and events and the impact they may have on the Company and its potential customers, including but not limited to the impact of Covid-19; the Company's ability to obtain adequate financing in the future; the impact of promulgation and implementation of regulations by the World Health Organization, the FDA and by other governmental authorities with functions similar to those of the FDA on the Company's operations and technologies; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; the Company's ability to secure regulatory approvals for its products; and our success in managing the risks involved in the foregoing items. Readers should also review the risks and uncertainties listed in our most recent Annual Report on Form 10-K and other reports we file with the U.S. Securities and Exchange Commission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Any forward-looking statement made by us in this press release speaks only as of the date on which such statement is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Contact:</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Ainos, Inc.<br>Lawrence Lin<br>Tel: (858) 869-2986 <br>Email: lawrence@ainos.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>SOURCE:</strong> Ainos, Inc. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>aimd_ex991img1.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 aimd_ex991img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %0 =0# 2(  A$! Q$!_\0
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M#JMQ9A;9+@G'E%MW)!ZD C\C0![G17#?%C5]0T'X/>*M:TB[>SO[/3Y)H)T
M)C<#@C/%?+\WQ(\>>%?!_A+QK:?&BW\4:EJ<T"W'AB6*!W(?[R_)\PQTSA3R
M/I0!]LT5Y!=?'30X/B'=> [7P[KU_J]G<PP7'V6U5XXED53YK-NX1=P!S@U0
MN_VD/ ]MJ$__ !*]<N= M+K['<>(8;+=8Q2YQ]_.2,]P/IF@#VZBO!-2^,VL
MP_M-Z7X!M-'O)_#LUBLAEM[8.9VDP5N ^?\ 4*" 6'?=UP*U6_:&\&+KCP_V
M;K1T&.^_LU_$8M/^)>MQG&W?G.,\;L8_#F@#V:BO)O%GQN\/^$_%EYX;AT76
M_$-_IT NM1&D6HF6QB(W!I"6'.T@X':N,\6?'N\M?B/\/['PSIFH:AX>UV$W
MDTD-ENENU(*A(]Q&"AR7& 1@<^H!]&45X]J'Q\\-VNOZI86/AOQ'J]CH]T+/
M4-3TZR$T%M+G!! ;>0#P2%^F:[SQ3J4MK\.]=U;2[@QRQ:7/<V\RCE6$3,K8
M/O@\T =+17QG\/?CAXUA^"_Q N?%6M27VN65C!>Z5<2JH;%Q^Z3&  =LFT_G
M4WA+XF^-#\%+K4?%WC34[?4[3Q9%IOVNVM8I9"-O,+ [1L)!)/)H ^QJ*\D\
M6?'+P[X5\4WOAN/0];\07NEP+<ZF=)M1*EA&0#F0EAS@YP.U2:W\;?"^GQ>'
MAH]CJWB:_P!?MC>66GZ7:EYS".KNK$;0"",'G(/I0!ZO17*^"?&NB^//"\7B
M#09)3;M(T,D4\?ERP2J<-&Z]F']17@"?%+Q1K7[3>MZ=/<>*-'\.^'8_,_L^
M"RC\MA&A9VN,\A),'8V?XEZ4 ?5-%>*:'^T9X+UO0[[Q"VEZUINA6-G]IDU*
M\M0L+/N"^0A#'?)E@,#CKS6EX1^.'AWQ1XHM/#=QHNM^']0U"$W&G+JUJ(5O
MHP,YC()YQS@XH ]9HKP9OVG_  3'9'49-!\1KI<%Z;&\U#[$#!9R;B!O8-SG
M&<+DX[9XKJ/!_P 8]!\7>,I_"L>EZQI&I"V%];+J=KY(O+<GB1.2<<YP0#CZ
M&@#U&BN&\=>/K/P.-/CDT75]:O\ 4I3%:6.E6WG22$#)))(50,CJ?IWP[P#\
M1M'^(FF7MYI=K>V%QIUTUG>V-_%Y<]M*O56 )'Z]C0!V]%?*GQ,\;:_;_M&W
M_A2?XM2> =!BTN&YCD,4;HTIQE?F'4Y)Z]J]"T/QQ;^"?A?!K^J>,-1^)2:C
M?&&QN=.L@\LSGY?* 3"@ HW+$<GZ"@#VFBO!->^/]O\ \*X\9:IHOAW5K+Q)
MX=1%FTS4K4![9I/N2NJMS&.I.>./45:\/?&PCX4^%]>UGP[XAU#7-6Q;)96F
MGCS;N54!:50"%$9SD'(SV'!H ]QHKYQ^(WQIEUGX!>(_$7@F;4?#VN:/J$%C
M=07<*QW%I(9E5E(.X<@D?G7H_P 1/&6I>$/@I?\ BJRL[F]U)-/#1FWA$GE2
M-'Q*X/&Q3\S>PH ]'HKXW\)_$'Q]_9'POO[CQ1K\TGB'Q L%\FIV\:+-'L0X
MA('S0G<<'@Y!Z5[]#\7O#L^D^/-26SOA'X)GE@OU*+NE,8))C^;D':<9Q0!Z
M517.^'O$UCXC\%6'BRU66&PO;47BK,H#HA7." 2,CV-?/OA2Y^,7QJT+5?'V
MA_$)O"=C]HEAT;2K>U1T81GCSF(R<G )Y[\8XH ^I**^;/'GQ!^(7@NS^%<W
MBR8V-_=:E)#K5OI:"=;U%"X"J!G+9^Z,<GTKNM#^.'A?6M/\3R7>E:QH]YX9
M027^FWMKBY"-]TJBD[L^GN.QS0!ZS17DOA;XU:3XH\41>%9O#>O>'-5O+-KZ
MQ35[41"[B )W(0Q[ GGT->)Z/\5/B!-\'_ &M3>)+E]0U#QC_9UU,53,]OD_
MNV^7&/IS0!]C45Y#X@^/7A?P_P"(M5TO^QM=U2TT5UCU;4["S\VUT]CV=L@\
M=\ XJSXE^-7AOP[XHL/#4.FZQKE_J>FKJ=@NE6XG%TC$A57Y@<D*6R<#'?M0
M!ZK17C\?Q^\#R?#&7QY)'J,,,=[_ &:VFO!_I9N_^>(3."V.>N, ]QBI_#OQ
MO\-Z]XQ7PE=:-KF@ZLM@^H3Q:K;"$6\:\G<=QSE?F!&1CN#Q0!ZS17CF@_'[
MPEKFO:;9+I>MV&F:O<&UTS6KVS\NSO91QL1LY!)'&0,^U>QT %%%% !7C/QA
M^'_B37M;\,>.O [6S^*/"T[216MTVV.\B;&Z,MV/'MPQY'%>S44 ?->H>&_B
MM\8/&?AB3QUX5M?"'AKP_=B_>!;L7$MW,N,<C@+U_ GKVZ;P'X+\8Z#KOQ=O
M6ACTZ[\0:A+<Z1=,ZNIRK^6Y SC!*D@U[=10!\9V?PK^*5WJO@[5-:\'WDNK
MZ+K"76K:K>:X+I[M=XYAC)VJH R0.2<5[;\+?!_B#PW\0/B9JFL6(@M-;UC[
M98R"16\V+YN>#QU'!KU^B@#Y]\8?#GQ=JOQT\1>)+#3UDTS4/"%QI,$WG*-U
MRR,%4@G(&2.3Q6%J'PO\:7'P2^%'AV'1P=2\/:Q!=ZA"9D'EQJ7RP.<-]X=*
M^GZ* /FBX^&_CBZ\=_%C0)M&1=!\<PF2VUM;A=MM(L?R*\?WB"QP?3'?-8_P
M[^%?BRU\6^$(]<\ _88_#C>9<:E=:]-=(\BX"O;1!MJ9P,@C';C%?5]% 'A7
MPU^'_BCP]\-OB#HNIZ>EOJ.L7U_-:H)582K*A$9W X&3Z]*X;4/@QXTNO@1\
M.[(:6)M>\)W,DUQI0O?L[7$;N2RI,I^5L!<$'N?H?JZB@#Y23X2>+-0^&WQ&
MD@\$C1M7UZWAMK*VN-6>\N9D216/G22,5R O&,>E=IXX^'/BK5/AY\.;SP_:
MV\OB/P8]M<_V;<R!([DK&JR1[N@.5&#TZU[S10!\X6G@GX@>-?B%XA^(WBCP
M_#X;F/AV?1=.TI+I9GE9U?YI'  ^\QQ^'ISE7WPM\;3?LZ?#OPC!HZG6-&UJ
M"\OK?SD&R-6E)8'.&X9>GK7U)10!Q7Q1T/4?$WPC\3Z!I$'GZA?V$D,$3,$W
M.1P,G@5ROPO^$'A'PWX.\.W>I>"],MO$]K:1K<W'E*T@F PS;O7/>O7Z* /&
MO!/@?7M,^.WQ,\1ZM8"'2M?6W6SN%D5C(JIM;@<K^->51_#GXQ:-\+M4^"-A
MX7T^]TB^NF\KQ&;P!$MVD#DM%C=OX_7O@&OKJB@#YXNO ?C+PK\;_ _B#1=#
M.O:'8^'XO#]W*MRL4EN Q#2X/+84@@#KR,BO-K'X$>,-'@E\$3>"1K=FVI^<
MFKS:[-'9/;;L@O;(PQ(/Y^O6OM"B@#YROO"_Q,^'_P 5O%WBCP+X6MO$]CXJ
MMHEC,MVL3V$\:;1O#??3//'4=QW=XJ\)_%+_ (2+X6^./[!LO$&KZ&MQ'JMI
M93+:HK2XPR;L\ 9SCN.G/'T710!\C>/?A9XZU+QIKNI:!X$_LS7KRZ\[3_$6
M@ZPUG$4+ [KF%B29,9W%<9)_/Z+U+2=9N?A->Z)=3K?:W/HTEH\G"":<PE<^
M@RQ_6NNHH ^-%_9_\:7'_"K6FT_[/#:01V?B*)9U^5(KHRQY /SY#=LXQ6MJ
M'P=\?2?#WQ%H\.CHUS<^.!K4*"X3#6F6^<'.,\CY>M?6M% 'SIJGAWXI> _B
MKXT\1>!_"MIXFLO%\4<D<DMTL+:?<*NW]XK??3))P.HP,BL?QQ\+_']]XH\*
M>/;[1%\1ZA#I7]GZO8:1J#:8Z2;F99(7!Z?-@CVZ<\?4=% 'E?P6\&ZAX-\#
M3PZIHEOHM_?W;W4UK;W4ER!G !9W))<@<X.*YV'P'XI7XS?%+Q VGK_9OB'1
M8[33YO-7]Y*(0A4C.5YSUKW:B@#YOM_@]XDU3]D>Q^'5Q'#IGB*T;[0D4K!H
MVE28N%9ER,,#C/."1Z5):>&_B=\0/B9X)UKQEX2MO"NG^#M\I,=VMP]Y,0H^
M7;]U/D''/?K7T910!\H/\(O'C?LW^)/!W]BH-:O/$9U".#STP\'FHV[=G'0'
MCK7HR^"?$B_M,:!XT^P :':^&?[.DF\Q<I-N8[=N<]QSTKVFB@#Q'XV>'_B!
MK>K^&9/#MK>ZKX:@DD_M;2-/U'[!-<DXV-YG!*CG(!_GD5O@#X%\3>"9/&L/
MB#0ETB/5-16\LXXKK[0@C*GY-^=Q*Y );!->[T4 >&W'PUOM3_:FU#QAK7A^
MTU#PS-HJ6L;W*QRCS@1_ <D=#SBK?Q>\*^+I/!NCZ;\-[-H-/@OQ)JFE:7.M
MA)=VY'*QR#&WGKC&<Y[5[/10!\F>'?@_XX5?BI"?"RZ';^*='6+389-0^U;9
M ,>7)(3NW'J2>,D\XJU>>&?C%??#KP%IDGA>^@TW1=UGK.A6.L+;37R*J"*4
M2KCY<ALH#Q[YR/JFB@#XY7X+_$$?"3XE>'8_"T5C>:WJUI?Z?:I?+*GE+)N9
M?,8Y)4=2V":^C/&&AZIK'P5UGP[86^_4KO19+2*%F"YE,.T*2>!SWKNJ* /F
MZ3X:^,_^$3^"%HND@S^%;U)=43SES HQR.?FZ'IFLG5O ?Q4TN\^+/AO0O"E
MKJFG>.)I;JVU-KY8E@#AMR%",EL-@=!GG.*^IZ* .'^&N@WFC?"#PYX=URU\
MF[M=.2UN8=P;!"X89'6O%]!\._&SX0Z+J_@'P7X7L/$6CW%Q+)I.KM>")K,2
M?\]8S]XKU[#.>2.!]044 ?/&K_#KXB:A%\))M;NSXBU+P_JC76KWA9$*(VTC
M P-^,8SC/'-0>(?A_P#$QOB'\5_$'A-1IUWKNFV<6D7PG569HQ&)%!ZHQ"L
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M=>T^WU&PFXDM[F,.C8Y'![CUK+\+^ /!?@PRMX5\-V6DO/\ ZQX(\,_L2>:
M/F?PC\%_&-G>>&O#6N> P\&CWPGN-7EUZ:2UD16RDD$"L DGU&/4<FOL.BB@
M HHHH **** "BBB@ HHK.U#5-,TF!9M4U"UL(F;:KW,RQJ3UP"Q'- &C15&Q
MU+3]4MOM6FWUO>09V^9;RK(N?3*DBKU !15*.[M9KJ>UANHY+B#;YL2N"\>X
M9&X=1D=,U=H **** "BJ5O>6MUYHMKJ*X,4ABD\IPWEN.JG'0CT/-+->6EL\
M$=Q=10R7#;(ED<*9&QG"@]3CL* +E%,9E7&Y@,G R>II] !16=?:KI>E"$ZE
MJ%O9>>XBB^T3+'YCGHJ[B,GV%/O]2T_2;-KS5+^WLK9>&FN95C0?5F(% %ZB
MLUM8TE=.34GU2T6R?&RY,ZB)L],-G!JO_P ))X=CCCFDU[3TCESY;M=1A7P<
M'!SS@\4 ;5%84_BCPS:B,W7B#3(!*OF1F2[C7>N<;AD\C(//M5[^TK#-L/MM
MN3=Y-N!(O[X 9^3GYN.>* +]%4[B[M;:2'[5=16YFD$,?F.%\QST1<]2<'@<
M\4RWU*PO+FXM;2_M[B>V;;-%%*K-$?1@#E3]: +]%4H[RSDNYK..ZADN8 IE
MB60%XPW*[AU&>V>M7: "BJ5Q>6EK+"MS=10&>011"1PID<]%7/4\'@5=H **
M*9N5F*A@2.H[B@!]%%% !13 REBH8$CJ,\BGT %%4[>\L[J29;:ZCG:!S%*(
MW#&-QU5L=#ST-7* "BJ,=]93RW$<=U%(]LP295D!,3$9 8=C@]Z6&\M+B>>"
M"ZBEFMV"S1HX9HB1D!@.AQSS0!=HJG/=6=K)!'<74,#W#^7$LD@4R-UVJ#U/
ML*SH_%'AF:]6QA\1:9)=,_EK EY&7+=-H7.<^U &[168-8TEK#^T!JEH;/?Y
M?GB=?+W9V[=V<9SQCUK3H ***HI?6<E_+8QW4+W<*AI(5D!D0'H2O4 T 7J*
M*I6=Y:WUNMS9W45S Q*B2%PZD@X/(XX((H NT5FW&JZ7:R30W>I6T$D$7GRK
M),JF./.-[ GA<\9/%7E99$#HP92,@@Y!% $E%%% !13&8*I9B !R2>@J"UNK
M6^M([JSN(KF"0926)PZ,/4$<&@"U1110 4444 %%%% !1110 4444 %%%% !
M7S_^TL(6L/A^+A](2+_A)8MS:TNZR \J3_7#(RGKS7T!7-^(F\)R?V?8^*HM
M.G%]<B"S@OXTD$LY4D*@8'YL _K0!\K:'XLNO!,'Q0O/"\_AT7K-IC'4/#4?
MF:-812/Y32"+D>8H9F;D@\>ASU.I_$[Q=H.G^,-)TSQU;^(;'3YM,CC\5&WA
M86 NI-LV_P L")RBC<..-W.:^C[/0=%L+"33]/TBRL[.7(DMX+=(XWR,'*@8
M/%8/AR[^'^K0ZMX:\+#1KBWLI##J%A90Q^5&YR"KJHVDG!!^E 'SOI^O:YH'
MBGXJ>*_#_BX>)'T2[T2YOKV*&%O[1LTC99XVV#;N5"?F3'W#7MGPQUSQ!XT\
M*Z[XGNM3D6PU:_N1H0$*J;:S3]W$^,9)8JS_ #9ZBM?Q%\/]/UCPE=^'=%N/
M^$7AOD6"YFTJVAC>6 *5,7*D $,1D<CM6WHEEHOAO3]-\)Z7)%#'96BQV]J9
M 9/)0!=V.I'3)]3[T ?*TGQX^(UC UQ=;Y$TRUE\-7BBW3,FO$3>5(!M^[^[
M3(''S'BMN\^(GQ-TWQ]=Z/-XB@^UZ)>:?IWV*Z:SMXM2\Q$\V1PY$I:0EMAB
M&T8 ]:^E6T/16W[]'L6\RX%V^;=#NF'24\<N/[W6L^5/!]YXXCMI[;3+CQ1:
M6PNDWPHUU# 6*APQ&X+NR.#UH ^?V\;:Y8PZK8VNM6GABRO_ (C7^E7FMQ6L
M*_9(50,N25V>8Y&WS'!/K60/$7B3QO?^%_.\8)?W%G\0+O3;#68K6(#[.EH-
MKJ@&PDY8@G(R<\C KZ(\4^!;/Q-H1T^SOIM D-W]L>6PBB*SR=_.C=624'C(
M8'D#GBLKPCX;\%^"9+KP[-K$&I:ZLDGB*\GU'RA.K2'8UP  %B7Y=HV@  8H
M \-N/$'B37-7\$?\)!XXFMSHOC?4=%.H&*&,3+$A\N20;=@<@E.F/FZ9YKUK
MXH>)M:L?'7A?PK!XN7P3I.J0W5Q<:T\<3%I(@NR!6E!12<ECGD@8%=MY?@>_
MOU\/?9]&NKV5!K*V?DQN7#-M^TA<<Y;C?U]ZVM3TC2=:M/L>L:9:ZE;;@WDW
M<*RID=#A@1F@#Y;TJ[USXD_$/X-ZQXBU@2.YU8(5LXC#=K;,,7"(ZG'FK@'^
M[MRN,UW?Q.&@M\?_  2OQ"^R_P#"(?V==?9AJ6/L9U#<N/,W?)N\O[N[OTKV
MG^S--6YMIA8VXELT,=LXB7= I&"J''R@@ 8'I2ZEI.EZS9-8ZQIMKJ-HQ!,%
MU"LJ$CH=K B@#YHU[3?A;KW@/3=(\%^)+'PUX9;Q<\F_5K62XT^\N$C;,<(9
MA'Y))R!N5"0<<U1NHO#GBGX#Z!9MX-\-IK.J:V_AG2KVTL%%NJO.WF7D"G.T
M%%=QSC=S[5]/S>']"N-%71;C1K";2U 5;*2V1H0!T 0C;^E2?V1I>VSC73;8
M1V)#6J>2N("!@%!CY>"1QB@#Y7\>:#H/AWX\Z7X=L1X)M-.T_P '16]NGC)/
M,M<"Y<#;R/WIY.>XW5D>"]:T72U^"EUJ%]!8V&EZSKEO+?3W"K:.?+^_"[8
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MJG/7YABOJ/RT9MQ52<;<D<X]*/+C\P2;%W@8#8Y H ^5_"/B[QU??&B&UO\
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MG@=<9)I)/'FFS?M":HMO\1/$MII.E2S;M,>YDE;5;WG]Q;0[-JQ(00-Q^8X
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MXZ?\*MT4 5/[0M/^>W_CI_PH_M"T_P">W_CI_P *MT4 5/[0M/\ GM_XZ?\
M"C^T+3_GM_XZ?\*MT4 5/[0M/^>W_CI_PH_M"T_Y[?\ CI_PJW10!4_M"T_Y
M[?\ CI_PH_M"T_Y[?^.G_"K=% %3^T+3_GM_XZ?\*/[0M/\ GM_XZ?\ "K=%
M %3^T+3_ )[?^.G_  JL=:TM;M;-KZ$7++N$);]X1ZA>N/>M2N4D _X6W;G
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M_AG_ (2C_A'QH*FY^SBZ,@@7RPA8KUSUR,8Q0(ZOTH_W:RO^$;T#/_((M?\
MOV*Y71=/L;SQEXFL;C2X#;6$L*0AE)'S1*QP"H'4^II#23O=V/0?PH_"L?\
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MH+8#..N?*+#_ +ZKRSX@_LX+J?CC1I])\<7\%N(U@9;Z5[F2VV[W#!\_*I.
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M^8?4=_P_*N?:'26\<#7EFB:=;06X019D)W'H>N>>F*VB_B/'_'IIO_@1)_\
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M?X4"-2BLO^VX?^?'4?\ P#D_PH_MN'_GQU'_ , Y/\* -2BLO^VX?^?'4?\
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MM>U#>+/3K:2ZG\M=S;$4LV!W.!7 M\</ \.DWVIZ@VIZ8+46[+;WEBZ37"W
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MKGWU;1_#^GV=K.([*+[,TJ)#"5B1$ +8Q\J]>!GZ9J2/Q!ILC:8JM)NU,,8
M4Q]W&=WIU ]Z &_\U#;_ +!8_P#1IKH*Y:6_L[?XANMQ>01$:8,AY%4C]Z?4
MUM_VOI7_ $%+3_O\O^- %ZBJ/]KZ5_T%+3_O\O\ C1_:^E?]!2T_[_+_ (T
M7J*H_P!KZ5_T%+3_ +_+_C1_:^E?]!2T_P"_R_XT 7J*H_VOI7_04M/^_P O
M^-']KZ5_T%+3_O\ +_C0!>HJC_:^E?\ 04M/^_R_XT?VOI7_ $%+3_O\O^-
M%ZBJ/]KZ5_T%+3_O\O\ C1_:^E?]!2T_[_+_ (T 7J*H_P!KZ5_T%+3_ +_+
M_C1_:^E?]!2T_P"_R_XT 7J*H_VOI7_04M/^_P O^-']KZ5_T%+3_O\ +_C0
M!>HJC_:^E?\ 04M/^_R_XT?VOI7_ $%+3_O\O^- %ZBJ/]KZ5_T%+3_O\O\
MC1_:^E?]!2T_[_+_ (T 6F1&(+*&(Y&1G%251_M?2O\ H*6G_?Y?\:/[7TK_
M *"EI_W^7_&@#/OK=8]32YAB7S40R#"\M@C(_$$UKQR)-"LD;;D8 @^HK)?5
M-*DU5/\ B9VG^I;_ );+_>'O1:ZEI\-Q);KJ%L8?]8C"5< $\CKZ_P ZK=&L
MO?BEU2_ \[\0_P"@?$2\UBU8-,NS**W.8(A*5P.[1-./RKUBWFCN((YX6#QR
M*&5AT((R#7G_ (J;2+6VN]>MKF W%K=07K$3 [U3"R8&?^>9<<5K>%=4T^UT
MZ?1Y=0M\Z9.UO&S3J=T)PT1SG^XRCZJ:A+5Q[6?WBK*W+/NK/Y;?@=E2UA6/
MB/2KRV,RWD,0#M'B69 258J3PQXR#5_^UM*_Z"EI_P!_E_QIF2=U=%ZBJ/\
M:^E?]!2T_P"_R_XT?VOI7_04M/\ O\O^- R]15'^U]*_Z"EI_P!_E_QH_M?2
MO^@I:?\ ?Y?\: +U%4?[7TK_ *"EI_W^7_&C^U]*_P"@I:?]_E_QH O451_M
M?2O^@I:?]_E_QH_M?2O^@I:?]_E_QH O451_M?2O^@I:?]_E_P :/[7TK_H*
M6G_?Y?\ &@">?_CUE_W#_*J>CY_L#3_^O:/_ -!%4M8U33)-!U!$U*U9FMY
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MOEPV<<GDDG&/EQDYS0!Z+16%)I]G9ZEITEI:10.TS*S1KM)'E.<'VR!^5;M
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MCNKF);Q9=/:4W4K%69?,C/WN@9",9YW"NSB"O>WD;J"&900>XVBN:\41R_\
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M$S>0Y\LF3D8&<?)W. #G)[5U']BZ3_T"[7_OTO\ A1_8ND_] NU_[]+_ (4
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M /QRM:B@#)\GQ'_T$-._\!'_ /CE'D^(_P#H(:=_X"/_ /'*UJ* ,GR?$?\
MT$-._P# 1_\ XY1Y/B/_ *"&G?\ @(__ ,<K6HH R?)\1_\ 00T[_P !'_\
MCE'D^(_^@AIW_@(__P <K6HH R?)\1_]!#3O_ 1__CE'D^(_^@AIW_@(_P#\
M<K6HH R?)\1_]!#3O_ 1_P#XY1Y/B/\ Z"&G?^ C_P#QRM:B@#)\GQ'_ -!#
M3O\ P$?_ ..4>3XC_P"@AIW_ ("/_P#'*UJ* ,GR?$?_ $$-._\  1__ (Y1
MY/B/_H(:=_X"/_\ '*UJ* ,GR?$?_00T[_P$?_XY1Y/B/_H(:=_X"/\ _'*U
MJ* ,GR?$?_00T[_P$?\ ^.4>3XC_ .@AIW_@(_\ \<K6HH YZ.WUY;F9S=V2
MY(.XVS$-@8X'F<5E>(Y/$6FZ1>7MJUG>7)MW"0"V?$KA6*+C?U8_+^-=D.O-
M4]06/^SYC*^U54MN_ND<@_ABGOH:TIVJ*35UIH>*?#,>+M?\$:OX3U*UATN*
MP400B:WD,@9MS@Y+C!4[2./2O2+/4M:OO"?]K&YLR3;LTL/V9@RNH(=,[^H8
M$=.U8[WR:?J5OXHA=A;L1::DH!PJ%B8I#_N,2"?[KG/2M$,-/N_$VDDXCN(&
MU&W&>SJ1(/P=<_\  Q44XN*Y9.[7Y&F9->W]M"*BI:66R:7^?YFO8_\ "076
MFV]PMW8PB2)6"-;NQ (XR1(*H^*(==_X1J[\V^L63*<+:N#_ *Q?^FE=!H__
M " -/_Z]X_\ T$50\7*K>%;M6 (S'P?^NBUHOB.%N\6WV+7D^(O^@AI__@(_
M_P <H\GQ'_T$-._\!'_^.5JCH*6I-3)\GQ'_ -!#3O\ P$?_ ..4>3XC_P"@
MAIW_ ("/_P#'*UJ* ,GR?$?_ $$-._\  1__ (Y1Y/B/_H(:=_X"/_\ '*UJ
M* ,GR?$?_00T[_P$?_XY1Y/B/_H(:=_X"/\ _'*UJ* ,6:'Q%]FEW:AI^-A_
MY=']/^NE6=%_Y%[3?^O:+_T$5<N/^/6;_</\JJZ+_P B_IW_ %[1_P#H(H O
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R!U;Q FM0VT
MUK']G:\EA/E0ON>+";&!/'&YBQR/N\9KKZ* .0N+N^A^(CB#2I+D#3%^9947
M/[T]B:V/[2U;_H7I_P#P(B_^*JM_S4-O^P6/_1IKH* ,C^TM6_Z%Z?\ \"(O
M_BJ/[2U;_H7I_P#P(B_^*K7HH R/[2U;_H7I_P#P(B_^*H_M+5O^A>G_ / B
M+_XJM>B@#(_M+5O^A>G_ / B+_XJC^TM6_Z%Z?\ \"(O_BJUZ* ,C^TM6_Z%
MZ?\ \"(O_BJ/[2U;_H7I_P#P(B_^*K7HH R/[2U;_H7I_P#P(B_^*H_M+5O^
MA>G_ / B+_XJM>B@#(_M+5O^A>G_ / B+_XJC^TM6_Z%Z?\ \"(O_BJUZ* ,
MC^TM6_Z%Z?\ \"(O_BJ/[2U;_H7I_P#P(B_^*K7HH R/[2U;_H7I_P#P(B_^
M*H_M+5O^A>G_ / B+_XJM>B@#(_M+5O^A>G_ / B+_XJC^TM6_Z%Z?\ \"(O
M_BJUZ* ,C^TM6_Z%Z?\ \"(O_BJ/[2U;_H7I_P#P(B_^*K7HH R/[2U;_H7I
M_P#P(B_^*H_M+5O^A>G_ / B+_XJM>B@#(_M+5O^A>G_ / B+_XJH9;S4IHG
MBD\.S,C@JP-Q%R#_ ,"K<I3TH!:'#FQN+C3I[6/09?*G#QRJTT9C<$D%6&[/
M0D9%<QJEUJNDZ+$UY:M-=:0LEK-*US&#-:RC:KMWR"(R3CJC>M>HV/\ QZ_]
MM)/_ $,UYW\64;3?#<OB2UNHK6Z@C-LS2\"2.0X Z=5;##\1WI\RC+FD=#O7
M3HRN[NZLKNZV2]3JM*U#6%T.Q63P_)D0(/EN(R/NCU(K&\:^)?[-\+W;ZI8_
M9$^3[]Q$6;YUX"ALD_2LGP':?V]X8LFU3Q%-?N%*@6%ZRV\P& 3E0K%AT8$]
M?K6IXH\%^%$\,S2?V':EXV4K(ZY;)=0<L3D_B:N/+S+6_H>=7C6A%Q4;.W6Z
M?S5CIH]6U"6-9(=#EDC8!E=;B(A@>A'S5-_:6K?]"]/_ .!$7_Q58_BJ_;P=
MX!N;K188(18)$D,<@)C1=ZKC .< &N>7Q5XLOK+4ET>.SU4V=X(6O[./<K1F
M-6)CC+X=E)((W=A2Y'+WEL6JBC[LMSN/[2U4#_D7I_\ P(B_^*I?[2U7_H7Y
M_P#P(B_^*KD?$%_>+\-;"<ZC>!9[JWCO;R6/[+,D+3 2D@8\OC(XZ#\ZKZ#X
MDN+'P%>-"TFKWL,UU_9MOO,LUU DQ2-_[SJ,C+>@HY)./,N]A^T7-9]KG:_V
MEJW_ $+T_P#X$1?_ !5+_:6K?]"[/_X$1?\ Q5>%RZWJLWA_[+-JU[%.-4O1
M)<7TDEE&Y6+(!8'*L&Y6/IG@ULIJVL'QAH4D.JW%Q<7<]D/*DN-LB6S09E22
MWZ9)RY<9 XY[5HZ+74S5=/H>M_VEJW_0O3_^!$7_ ,51_:6K?]"]/_X$1?\
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M3_SVE_\  >3_ .)K5HH RO\ A(=)_P">TO\ X#R?_$T?\)#I/_/:7_P'D_\
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MMI]JUQ%/Y?[R.4S*=Q^^4*$_]\DU>HH *RK'2K.QOKN[MHV66Z;<Y9B0.2Q
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M33K86ZW,QGD522"Y !//3H.E:M% !1110 4444 %%%% !1110 4444 %%%%
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>aimd_ex991img2.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 aimd_ex991img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $\ :0# 2(  A$! Q$!_\0
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M5JT  Z44=J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.3@>9S6#XP\)Z[JGB:XO++)BN/L"H^X#R/(N#)(?7E3QCJ>*MZIIVK:KXO\
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M<K\RL9XFC3IVY)<U[_\  .;_ .%?^%_^?>^_\&=U_P#'*/\ A7_A?_GWOO\
MP9W7_P <KJJ*T.0\[N-"T_P_X\\+?V2UW"+J2YCF1[V:59%$#, 5=R." :]$
MKD?$'_(^^"_^N]U_Z3-774 %%%% !1110 4444  Z5RFM?\ )1_"?_7*]_\
M0$KJQTKE-:_Y*/X3_P"N5[_Z E '5CI10.E':@"#R+?_ )XQ_P#?(H\BW_YX
MQ_\ ?(K":_\ $X9@OA^U9<G!^WXR/^_='V_Q3_T+MK_X'_\ VNHYEY_<S;V4
MNZ^]&YY$'_/&/_OD57U#3[/5M)NM)U"W2XL[J)H)H6'RNC#!7\C64NH>*O\
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M\--!\.^)-,UO2[F]C?3='30X+=G5H_LRMN&?EW%MW.[-=W0!R/B#_D??!?\
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MBB@ HHHH .]%'>B@ HHHH Y'Q!_R/O@O_KO=?^DS5UU<CX@_Y'WP7_UWNO\
MTF:NNH **** "BBB@ HHHH !TKE-:_Y*/X3_ .N5[_Z E=6.E<IK7_)1_"?_
M %RO?_0$H ZL=**!THH **** "BBB@ HHHH **** "BBB@ J":*.XA>&:-7B
MD4JZ,,A@>"#4]% ',_\ "O\ P.!C_A$M)Q_UZ)_A2_\ " >!_P#H4M)_\!$_
MPKI:* .:_P"$ \#_ /0I:3_X")_A1_P@'@?_ *%+2?\ P$3_  KI:* .:_X0
M#P/_ -"EI/\ X")_A1_P@'@?_H4M)_\  1/\*Z6B@#FO^$ \#_\ 0I:3_P"
MB?X4?\(!X'_Z%+2?_ 1/\*Z6CO0!S7_" >!_^A2TG_P$3_"C_A / _\ T*6D
M_P#@(G^%=+1WH YK_A / _\ T*6D_P#@(G^%'_" >!_^A2TG_P !$_PKI:*
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M@ HHHH Y'Q!_R/O@O_KO=?\ I,U==7(^(/\ D??!?_7>Z_\ 29JZZ@ HHHH
M**** .>\0ZU+HL6F21VJW"W>H06;AI-I02-MW#@Y()'''UKE-6^*6GZ//J$U
MS82-8VUQ<64<BO\ /+<0Q"1EVXX4Y*@YZJ<CFNPUS0X=<ALXYKB:W%K=Q7BF
M';EGC;<H.0>,]:QKSX?^'M1N[V:\MY9(KQYI&M]V$266,1R2+QD,54=\ Y(Y
M-!1I^'=>;6AJ5M<6ZP7>F79L[E%;>N[8K@J<#(*NO;UK#O=:T?4?BCX;L]/U
M6TN[FVCOA-##,KO%A4!W '(YXYKI-)T6WT6"Y6"22>6[G-S<3RD%YI" NXX
M'15& .@K)UB**/XC^%&CB16:.]R0H!/R)02=@.E% Z44 %%%% %>6:."%YII
M D:*69F. H'4DUD'Q9X9S_R'K'\)U_QK<*Y!!Y'H:@-K;G_EBGY"EJ5'E^U?
MY&9_PEOAG_H.V'_@0G^-)_PEGAK_ *#MA_X$)_C6K]EM_P#GW3_OD4?9+?\
MY]T_[Y%+4N]/LS*_X2SPU_T';#_P(3_&C_A+/#7_ $';#_P(3_&M7[);_P#/
MNG_?(H^R6_\ S[I_WR*-0O3[,RO^$L\-?]!VP_\  A/\:/\ A+/#7_0=L/\
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M7_)1_"?_ %RO?_0$H ZL=**!THH **** "BBB@ HHHH **** "BBB@ HHHH
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MCX3U92P0D%K?*[C@@_O?X>I]NF:T,3HJ.]<ZVO:@L;-_PB>KL0KMM#6^3AL
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M$U#3[IO$T=A?6UU#%K,S!H9EDXD1),D@]RS8_P#K4 =U12 @C(Y%+0 4444
M%%%% !WHH[T4 %%%% '(^(/^1]\%_P#7>Z_])FKKJY'Q!_R/O@O_ *[W7_I,
MU==0 4444 %%%% !1110 #I7*:U_R4?PG_URO?\ T!*ZL=*Y36O^2C^$_P#K
ME>_^@)0!U8Z44#I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'4#*/,$-QB+8F[GYN_3M7H-9\FI6,6IP:;)>1)>SQM)% 6&]T7&Y@.X&1^=
M',75CX^OK26TNIO#DD$RF-U\F<94C!'WZ72['QY9V$=O>ZCI=W*@V^:(9%+
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M_P"*H\OXC?\ /QX;_P"_,_\ \576=Z* .3\OXC?\_'AO_OS/_P#%4>7\1O\
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I HHHH **** "BBB@ HHHH **** #O11WHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>amar-20211207.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12-08-2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:amar="http://amarbio.com/20211207" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://amarbio.com/20211207">
 <annotation>
  <appinfo>
   <link:roleType roleURI="http://amarbio.com/role/Cover" id="Cover">
    <link:definition>000001 - Document - Cover</link:definition>
    <link:usedOn>link:presentationLink</link:usedOn>
    <link:usedOn>link:calculationLink</link:usedOn>
    <link:usedOn>link:definitionLink</link:usedOn>
   </link:roleType>
   <link:linkbaseRef xlink:type="simple" xlink:href="amar-20211207_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="amar-20211207_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="amar-20211207_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="amar-20211207_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
  </appinfo>
 </annotation>
 <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
 <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
 <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
 <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
 <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
 <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
 <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
 <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
 <import namespace="http://fasb.org/srt-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" />
 <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
 <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
 <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
 <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
 <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
 <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>amar-20211207_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12-08-2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://amarbio.com/role/Cover" xlink:href="amar-20211207.xsd#Cover" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://amarbio.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>amar-20211207_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12-08-2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://amarbio.com/role/Cover" xlink:href="amar-20211207.xsd#Cover" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://amarbio.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>amar-20211207_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12-08-2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>amar-20211207_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12-08-2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://amarbio.com/role/Cover" xlink:href="amar-20211207.xsd#Cover" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://amarbio.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>aimd_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amar-20211207.xsd" xlink:type="simple"/>
    <context id="From2021-12-07to2021-12-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <startDate>2021-12-07</startDate>
            <endDate>2021-12-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-12-07to2021-12-07">0001014763</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-12-07to2021-12-07">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-12-07to2021-12-07">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-12-07to2021-12-07">2021-12-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-12-07to2021-12-07">AINOS, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-12-07to2021-12-07">TX</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-12-07to2021-12-07">0-20791</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-12-07to2021-12-07">75-1974352</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-12-07to2021-12-07">8880 Rio San Diego Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-12-07to2021-12-07">Ste. 800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-12-07to2021-12-07">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-12-07to2021-12-07">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-12-07to2021-12-07">92108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-12-07to2021-12-07">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-12-07to2021-12-07">869-2986</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-12-07to2021-12-07">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-12-07to2021-12-07">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-12-07to2021-12-07">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-12-07to2021-12-07">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-12-07to2021-12-07">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139656827821512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AINOS, INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001014763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  07,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-20791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-1974352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8880 Rio San Diego Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Ste. 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">92108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">869-2986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">TX<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" ",=8A3EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04
M" ",=8A3)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM
M?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(H
MND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++
M3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$
M%     @ C'6(4V60>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&UL
MK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QX
MWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#
M4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$
MJ+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:
M!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U5
M9"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\
MUDX:?^:+X3]>?P%02P$"% ,4    " ",=8A3!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (QUB%,@
M XQ_[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( (QUB%.97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ C'6(4\LWET#* P
MYPX  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( (QUB%.?H!OPL0(  .(,   -              "  0T,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ C'6(4Y>*NQS     $P(   L
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64$L%!@     )  D /@(  &$3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="aimd_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://amarbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="aimd_8k.htm">aimd_8k.htm</File>
    <File>aimd_ex991.htm</File>
    <File>amar-20211207.xsd</File>
    <File>amar-20211207_cal.xml</File>
    <File>amar-20211207_def.xml</File>
    <File>amar-20211207_lab.xml</File>
    <File>amar-20211207_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "aimd_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "amar-20211207_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amar-20211207_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "aimd_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amar-20211207_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amar-20211207_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amar-20211207.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 21,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "amar",
   "nsuri": "http://amarbio.com/20211207",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_8k.htm",
      "contextRef": "From2021-12-07to2021-12-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "role": "http://amarbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_8k.htm",
      "contextRef": "From2021-12-07to2021-12-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line 2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://amarbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r3": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r4": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001654954-21-012947-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-21-012947-xbrl.zip
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M6\.X/"#<N3[ J=2;?QQ4K_BT@B0Q&?[DCL,\\Q/@MH %DMO$HV.@$V2^TO"
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MKI@@%[ 1644NK-_)@+LHM!SX@X=]'.".%L"@<>!JZC$1*'=&%*R5&LS,R&B
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MV4DFZQL=M$-JG <3B$,A[ 0#_KRDD_V36C!^F?.\,$]PA:N,PV*"P>8UR\Q
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M_G(/33/=_C\_W%;?Y=G'B\%AM<Z-MX ^&[-O;\S>?!=S0B\ZWO\/4$L#!!0
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M6(SP(SUOX[\;DTJQ$P&G[IZ4O9D$0D1.I6;07<W@B=_&IPQ/^_H$$)K]D,Y
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MC<J#QZQ+6;>)[NA3N./HUB5W]A=02P,$%     @ C'6(4W\W?R&L!0  .#0
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M^W1;&M("BLYW:7C>S80F[TN28/UCT>F%B?RD_J8EN83CO_.X^0]02P,$%
M  @ C'6(4Q\A>M-)!   Z"   !4   !A;6%R+3(P,C$Q,C W7W!R92YX;6S-
MF5USXC84AN\[T_^@LC?M3&UCTW8W3+([A&1WF,T' VF[TYL=81] L[+$2"+
MO^^1P80/&[0WJ^2"$/L]TGF?(Q0=?/EAF7/R#$HS*:X:<=AL$!"IS)B87#7F
M.J Z9:Q!M*$BHUP*N&JL0#<^O/_YI\M?@N#+]>".W,ATGH,PI*N &LC(@IDI
ML;?NJ3:@@F"C_F<]3YLD82MLOMM>OZ8:HZ0H8O!FO+US@^,1.2:I';D(C9,
M(Y-F\B(:RK%94 6$JG3*#*1FKB@G&6@V$003)VM#;7+#9B R1<GGD SQRG0[
M1E?.5HI-IH;\FOY&[/"D%SS</I'KN68"M"9#R><V!?T[Z8DT)!W.R<!&:#(
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M,#(Q,3(P-U]D968N>&UL4$L! A0#%     @ C'6(4W\W?R&L!0  .#0  !4
M             ( !A#4  &%M87(M,C R,3$R,#=?;&%B+GAM;%!+ 0(4 Q0
M   ( (QUB%,?(7K3200  .@@   5              "  6,[  !A;6%R+3(P
D,C$Q,C W7W!R92YX;6Q02P4&      < !P#  0  WS\

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
